ClinicalTrials.Veeva

Menu

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

Vertex Pharmaceuticals logo

Vertex Pharmaceuticals

Status and phase

Enrolling
Phase 3

Conditions

Diabetes Mellitus, Type 1
Impaired Hypoglycemic Awareness
Severe Hypoglycemia

Treatments

Biological: VX-880

Study type

Interventional

Funder types

Industry

Identifiers

NCT04786262
VX20-880-101
2024-513929-23-00 (EU Trial (CTIS) Number)

Details and patient eligibility

About

This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.

Enrollment

52 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  • Clinical history of T1D with > 5 years of duration of insulin dependence
  • At least two episodes of documented severe hypoglycemia in the 12 months prior to enrollment
  • Stable diabetic treatment
  • Consistent use of continuous glucose monitor (CGM) for at least 3 months before Screening and willingness to use CGM for the duration of the study

Key Exclusion Criteria:

  • Prior islet cell transplant, organ transplant, or cell therapy

Other protocol defined Inclusion/Exclusion criteria may apply

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

52 participants in 1 patient group

VX-880
Experimental group
Treatment:
Biological: VX-880

Trial contacts and locations

23

Loading...

Central trial contact

Medical Information

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems